BRPI0812247A2 - Derivados de piridazinona - Google Patents

Derivados de piridazinona

Info

Publication number: BRPI0812247A2
Authority: BR; Brazil
Prior art keywords: pyridazinone derivatives; pyridazinone; derivatives
Prior art date: 2007-06-01

Application number

BRPI0812247-4A

Other languages

English (en)

Inventor

Frank Stieber

Oliver Schadt

Dieter Dorsch

Andree Blaukat

Original Assignee

Merck Patente Ges Mit Beschraenkter Haftung

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-01

Filing date

2008-05-02

Publication date

2015-06-16

2008-05-02 Application filed by Merck Patente Ges Mit Beschraenkter Haftung filed Critical Merck Patente Ges Mit Beschraenkter Haftung

2015-06-16 Publication of BRPI0812247A2 publication Critical patent/BRPI0812247A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Neurology (AREA)
Transplantation (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)

BRPI0812247-4A 2007-06-01 2008-05-02 Derivados de piridazinona BRPI0812247A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102007025718A DE102007025718A1 (de)	2007-06-01	2007-06-01	Pyridazinonderivate
PCT/EP2008/003550 WO2008145243A1 (de)	2007-06-01	2008-05-02	Pyridazinonderivate

Publications (1)

Publication Number	Publication Date
BRPI0812247A2 true BRPI0812247A2 (pt)	2015-06-16

Family

ID=39671665

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0812247-4A BRPI0812247A2 (pt)	2007-06-01	2008-05-02	Derivados de piridazinona

Country Status (16)

Country	Link
US (1)	US8367668B2 (pt)
EP (1)	EP2150539B1 (pt)
JP (1)	JP5485875B2 (pt)
KR (1)	KR20100027188A (pt)
CN (1)	CN101679303B (pt)
AR (1)	AR066770A1 (pt)
AU (1)	AU2008255328B2 (pt)
BR (1)	BRPI0812247A2 (pt)
CA (1)	CA2688518C (pt)
DE (1)	DE102007025718A1 (pt)
EA (1)	EA200901601A1 (pt)
ES (1)	ES2444218T3 (pt)
IL (1)	IL202376A (pt)
MX (1)	MX2009012708A (pt)
WO (1)	WO2008145243A1 (pt)
ZA (1)	ZA200909054B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102008062826A1 (de)	2008-12-23	2010-07-01	Merck Patent Gmbh	Pyridazinonderivate
DE102009003954A1 (de) *	2009-01-07	2010-07-08	Merck Patent Gmbh	Pyridazinonderivate
US20120129858A1 (en) *	2009-04-20	2012-05-24	Institute For Oneworld Health	Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
CA2782885A1 (en) *	2009-12-21	2011-07-14	Merck Sharp & Dohme Corp.	Tyrosine kinase inhibitors
EP2588107A1 (en)	2010-07-01	2013-05-08	Takeda Pharmaceutical Company Limited	COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
CN102731409A (zh) *	2011-04-08	2012-10-17	中国科学院上海药物研究所	一类哒嗪酮类化合物，其药物组合物、制备方法及用途
SG11201408324QA (en)	2012-06-12	2015-01-29	Abbvie Inc	Pyridinone and pyridazinone derivatives
WO2014031928A2 (en) *	2012-08-24	2014-02-27	Philip Jones	Heterocyclic modulators of hif activity for treatment of disease
NZ704799A (en)	2012-08-24	2018-06-29	Univ Texas	Heterocyclic modulators of hif activity for treatment of disease
CN103664895B (zh) *	2012-08-28	2018-02-27	中国科学院上海药物研究所	哒嗪酮类化合物、其制备方法、药物组合物及其用途
LT3057586T (lt)	2013-10-18	2020-03-10	Celgene Quanticel Research, Inc.	Bromodomeno inhibitoriai
KR102116107B1 (ko)	2013-12-30	2020-05-28	삼성디스플레이 주식회사	표시 장치
US9988421B2 (en)	2014-01-10	2018-06-05	Cornell University	Dipeptides as inhibitors of human immunoproteasomes
ES2726648T3 (es)	2014-02-25	2019-10-08	Univ Texas	Sales de moduladores heterocíclicos de la actividad del HIF para el tratamiento de enfermedades
EP3193904B1 (en)	2014-08-18	2025-10-01	Cornell University	Dipeptidomimetics as inhibitors of human immunoproteasomes
ES2764299T3 (es)	2014-12-09	2020-06-02	Inst Nat Sante Rech Med	Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (en)	2015-02-26	2016-09-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP6970085B2 (ja)	2015-10-15	2021-11-24	コーネル・ユニバーシティーCornell University	プロテアソーム阻害剤およびその用途
KR20180084478A (ko)	2017-01-17	2018-07-25	김민규	파일 인양을 위한 굴절케이싱 및 이를 이용한 파일 인양방법
EP3694605A4 (en)	2017-10-11	2021-10-27	Cornell University	PEPTIDOMIMETIC INHIBITORS OF PROTEASOME
ES2957383T3 (es)	2018-11-06	2024-01-18	Edgewise Therapeutics Inc	Compuestos de piridazinona y usos de estos
EA202191084A1 (ru)	2018-11-06	2021-10-19	Эджвайз Терапьютикс, Инк.	Соединения пиридазинонов и их применения
JP7671245B2 (ja) *	2018-11-06	2025-05-01	エッジワイズセラピューティクス，インコーポレイテッド	ピリダジノン化合物およびその使用
CN114105976B (zh) *	2020-08-28	2024-04-26	杭州邦顺制药有限公司	选择性rock2激酶抑制剂
WO2023091606A1 (en) *	2021-11-17	2023-05-25	Edgewise Therapeutics, Inc.	Pyridazinone compounds and uses thereof
EP4472624A4 (en) *	2022-02-03	2026-01-07	De Shaw Res Llc	PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RO79566A2 (ro)	1980-05-28	1982-08-17	Institutul De Cercetari Chimico-Farmaceutice,Ro	Substante din clasa 2-(3'-aril-piridazonil-1'5-metil-5-aril-(alchil)amino-tiadiazolului
RO79562A2 (ro)	1980-05-29	1982-08-17	Institutul De Cercetari Chimico-Farmaceutice,Ro	Substante din clasa 3-(3'-aril-piridazonil-1'5-metil-4-aril(alchil)-5-mercapto-1,2,4-triazolului si procedeu de obtinere a acestora
JPS5795964A (en)	1980-12-04	1982-06-15	Morishita Seiyaku Kk	Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en)	1981-05-14	1983-08-09	Warner-Lambert Company	Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
JPS5826802A (ja) *	1981-08-10	1983-02-17	Sankyo Co Ltd	農園芸用殺菌剤
DE4134467A1 (de) *	1991-10-18	1993-04-22	Thomae Gmbh Dr K	Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ES2131506T3 (es) *	1990-09-21	1999-08-01	Rohm & Haas	Dihidropiridacinonas y piridacinonas como fungicidas.
AU691673B2 (en)	1994-11-14	1998-05-21	Dow Agrosciences Llc	Pyridazinones and their use as fungicides
US5635494A (en)	1995-04-21	1997-06-03	Rohm And Haas Company	Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
BR9707495A (pt)	1996-02-13	1999-07-27	Zeneca Ltd	Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
AU719327B2 (en)	1996-03-05	2000-05-04	Astrazeneca Ab	4-anilinoquinazoline derivatives
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
WO1999010332A1 (en) *	1997-08-22	1999-03-04	Abbott Laboratories	Prostaglandin endoperoxide h synthase biosynthesis inhibitors
MXPA00004955A (es)	1997-11-19	2002-10-17	Kowa Co	Derivados novedosos de piridazina y medicinas que los contienen como ingredientes activos.
TWI241295B (en)	1998-03-02	2005-10-11	Kowa Co	Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en)	1999-01-07	1999-02-24	Angiogene Pharm Ltd	Tricylic vascular damaging agents
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
IL152682A0 (en)	2000-05-31	2003-06-24	Astrazeneca Ab	Indole derivatives with vascular damaging activity
KR20030022264A (ko)	2000-07-07	2003-03-15	앤지오젠 파마슈티칼스 리미티드	신생 혈관 형성 억제제인 콜치놀 유도체
WO2002004434A1 (en)	2000-07-07	2002-01-17	Angiogene Pharmaceuticals Limited	Colchinol derivatives as vascular damaging agents
GB0108102D0 (en)	2001-03-30	2001-05-23	Pfizer Ltd	Compounds
AUPR606401A0 (en) *	2001-07-02	2001-07-26	Fujisawa Pharmaceutical Co., Ltd.	Pyrazolopyridine compound and pharmaceutical use thereof
CA2462525A1 (en) *	2001-10-31	2003-05-08	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Type 4 phosphodiesterase inhibitors and uses thereof
MXPA04006781A (es) *	2002-01-18	2004-11-10	Pharmacia Corp	Piridazinonas sustituidas con darilo.
JP4890439B2 (ja) *	2005-03-07	2012-03-07	杏林製薬株式会社	ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
DE102005055354A1 (de) *	2005-11-21	2007-10-31	Merck Patent Gmbh	Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102005057924A1 (de) *	2005-12-05	2007-06-06	Merck Patent Gmbh	Pyridazinonderivate
DE102006037478A1 (de) *	2006-08-10	2008-02-14	Merck Patent Gmbh	2-(Heterocyclylbenzyl)-pyridazinonderivate
MX2009008531A (es) *	2007-02-16	2009-08-26	Amgen Inc	Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.

2007
- 2007-06-01 DE DE102007025718A patent/DE102007025718A1/de not_active Withdrawn
2008
- 2008-05-02 BR BRPI0812247-4A patent/BRPI0812247A2/pt not_active IP Right Cessation
- 2008-05-02 ES ES08758367.0T patent/ES2444218T3/es active Active
- 2008-05-02 KR KR1020097027591A patent/KR20100027188A/ko not_active Withdrawn
- 2008-05-02 JP JP2010509701A patent/JP5485875B2/ja not_active Expired - Fee Related
- 2008-05-02 MX MX2009012708A patent/MX2009012708A/es not_active Application Discontinuation
- 2008-05-02 WO PCT/EP2008/003550 patent/WO2008145243A1/de not_active Ceased
- 2008-05-02 CN CN2008800179692A patent/CN101679303B/zh not_active Expired - Fee Related
- 2008-05-02 EA EA200901601A patent/EA200901601A1/ru unknown
- 2008-05-02 EP EP08758367.0A patent/EP2150539B1/de not_active Not-in-force
- 2008-05-02 US US12/602,254 patent/US8367668B2/en not_active Expired - Fee Related
- 2008-05-02 AU AU2008255328A patent/AU2008255328B2/en not_active Ceased
- 2008-05-02 CA CA2688518A patent/CA2688518C/en active Active
- 2008-05-30 AR ARP080102271A patent/AR066770A1/es unknown
2009
- 2009-11-26 IL IL202376A patent/IL202376A/en active IP Right Grant
- 2009-12-18 ZA ZA200909054A patent/ZA200909054B/xx unknown

Also Published As

Publication number	Publication date
WO2008145243A1 (de)	2008-12-04
JP2010528995A (ja)	2010-08-26
CA2688518C (en)	2015-09-29
US8367668B2 (en)	2013-02-05
CA2688518A1 (en)	2008-12-04
EP2150539B1 (de)	2013-12-18
IL202376A (en)	2016-05-31
ZA200909054B (en)	2010-09-29
DE102007025718A1 (de)	2008-12-04
AU2008255328A1 (en)	2008-12-04
AU2008255328B2 (en)	2013-02-14
US20100179148A1 (en)	2010-07-15
JP5485875B2 (ja)	2014-05-07
EP2150539A1 (de)	2010-02-10
MX2009012708A (es)	2009-12-08
IL202376A0 (en)	2010-06-30
KR20100027188A (ko)	2010-03-10
EA200901601A1 (ru)	2010-06-30
AR066770A1 (es)	2009-09-09
ES2444218T3 (es)	2014-02-24
CN101679303B (zh)	2012-05-09
CN101679303A (zh)	2010-03-24

Publication	Publication Date	Title
CY2022017I1 (el)	2023-01-05	Παραγωγα πυριδαζινονης
FR24C1047I2 (fr)	2025-10-10	Derive de 4-pyrimidinesulfamide
BRPI0812247A2 (pt)	2015-06-16	Derivados de piridazinona
BRPI0821743A2 (pt)	2015-09-22	derivados de piridazinona
BRPI0923497A2 (pt)	2019-09-24	derivados de piridazinona
BRPI0820112A2 (pt)	2015-05-05	Derivados de isoxazol-piridina
BRPI0809992A2 (pt)	2014-10-14	Derivados de pirrolopirimidina
BRPI0820113A2 (pt)	2015-05-05	Derivados de isoxazolo-piridazina
DK2209786T3 (da)	2013-06-03	Pyrimidinsubstituerede purinderivater
BRPI0812155A2 (pt)	2019-09-24	derivados de espiroindolinona
BRPI0817935A2 (pt)	2015-04-07	Derivados de biarila
DK2069312T3 (da)	2013-02-04	Pyridazinonderivater
BRPI0813836A2 (pt)	2015-01-06	Derivados pirazólicos
EP2226315A4 (en)	2012-01-25	2-aminoquinazoline DERIVATIVE
BRPI0814236A2 (pt)	2015-01-06	Derivados de quinazolinamida
BRPI0812518A2 (pt)	2015-03-31	Derivados de indazolamida
BRPI0810202A2 (pt)	2014-10-21	Derivados de piridina
BRPI0820649A2 (pt)	2015-06-16	Derivados de isoxazalo-pirazina
ES2465673T9 (es)	2014-11-14	Derivados de pirimidina
BRPI0911161A2 (pt)	2015-10-06	derivado de piridazinona
DK2152370T3 (da)	2011-08-15	Aryletherpyridazinonderivater
ATE533761T1 (de)	2011-12-15	Imidazolidinonderivate
BRPI0820779A2 (pt)	2015-06-16	Derivados de 4-amino-pirimidina
BRPI0814718A2 (pt)	2015-02-24	Derivados de isoxazol-imidazol
ATE546446T1 (de)	2012-03-15	5-aminocyclylmethyl-oxazolidin-2-eins-derivativ

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.